- The National Institute for Health and Care Excellence has approved the life-extending drug Enhertu for NHS use in England after reversing its previous rejection.
- Roughly 1,000 women with HER2-low advanced breast cancer will now have immediate access to the targeted therapy following an agreed commercial deal.
- Clinical trial data showed that patients treated with Enhertu survived for around two years compared with 17.5 months for those undergoing standard chemotherapy.
- Charity Breast Cancer Now welcomed the decision as momentous, although campaigners highlighted that many patients tragically died during the delay.
- The drug has been available on the NHS in Scotland for more than two years, and its approval in England follows updated evaluation methods and cost-effectiveness thresholds.
IN FULL
